We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Actinium Pharmaceuticals Inc (ATNM) USD0.001

Sell:$5.18 Buy:$5.57 Change: $0.29 (5.14%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $0.29 (5.14%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $0.29 (5.14%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with other therapeutic modalities. Its clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Its lead CD45-targeted conditioning product candidate, Iomab-B, via the monoclonal antibody BC8, targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Its CD33 program is evaluating the clinical utility of Actimab-A, an ARC consisting of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (Ac-225).

Contact details

275 Madison Ave Fl 7
United States
+1 (646) 6773875

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$116.98 million
Shares in issue:
22.03 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Sandesh Seth
    Chairman of the Board, Chief Executive Officer
  • Steve O'Loughlin
    Chief Financial Officer, Corporate Secretary
  • Avinash Desai
    Chief Medical Officer
  • Arun Swaminathan
    Chief Business and Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.